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Introduction
Women with minor cytological lesions identified in a Pap
smear have a small but significantly increased risk of develop-
ing cervical cancer compared to women with normal smears.
Reviews of the natural history of cervical epithelial atypia or
low-grade squamous lesions suggest that the 2-year cumula-
tive risk of invasive cervical cancer is in the range of 0.10% to
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Abstract
Consistent evidence underlines the utility of human papillomavirus (HPV) DNA testing in the management of women with equivocal
 cervical cytological abnormalities, but not in case of low-grade lesions. We performed a meta-analysis including studies where the  
high-risk probe of the Hybrid Capture-II is used to triage these two cytological categories. The triage test-positivity rate reflects the
 colposcopy referral workload.Data were pooled on the HPV test positivity rate in women with atypical squamous cells of undetermined
significance (ASCUS/ASC-US) or low-grade squamous intraepithelial lesions (LSIL), derived from different cytological classification
 systems. The meta-analysis was restricted to studies, published between 1991 and 2007. A random-effect model was applied for meta-
analytical pooling and the influence of covariates on the HPV positivity rate was analyzed by meta-regression. The variation by age was
assessed within individual studies since age strata were not defined uniformly. On an average, 43% (95% CI: 40–46%) of women with
ASCUS/ASC-US were high-risk HPV positive (range 23–74%). In women with LSIL, the pooled positivity rate was 76% (95% CI:
71–81%; range 55–89%). In spite of considerable inter-study heterogeneity, the difference in HPV positivity between the two triage
groups was large and highly significant: 32% (95% CI: 27–38%). HPV rates dropped tremendously as age and cutoffs of test 
positivity increased. Other factors (cytological classification system, country, continent, collection method and year of publication) had
no statistically significant impact, except in LSIL triage where HPV positivity was significantly lower in European compared to American
studies. Women with LSIL, especially younger women, have high HPV positivity rates suggesting limited utility of reflex HPV triaging
these cases. Research is needed to identify more specific methods to triage women with low-grade squamous cervical lesions.
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0.25% [1, 2]. Therefore, careful follow-up of these lesions is
warranted.
The recognition of the strong association between persistent
infection with oncogenic human papillomavirus types and the sub-
sequent development of cervical cancer has prompted the detection
of HPV DNA as an alternative triage method [3]. A recent meta-
analysis of the accuracy of HPV DNA detection for cervical intra-
epithelial neoplasia of grade 2 or worse (CIN2), using the high-risk
probe of the Hybrid Capture II assay (HC2, Qiagen, Gaithersburg,
MD, USA), in case of equivocal cytology demonstrated that the
pooled estimate of the sensitivity and specificity was 94.8% (95%
CI [CI]: 92.7–96.9%) and 67.3% (95% CI: 58.2–76.4%), respec-
tively [4]. The pooled sensitivity for predicting presence of CIN3
was 96.4% (95% CI: 93.5–99.9%) and the pooled specificity was
56.5% (95% CI: 45.5–67.5%) [5]. The sensitivity of the HC2 assay
was 16% (ratio  1.16; CI: 1.04–1.29%) and 13% (ratio  1.13; CI:
1.05–1.22%) higher than that of repeat cytology at cut-off atypical
squamous cells of unspecified significance (ASCUS)/borderline
dyskaryosis or worse for, respectively, CIN2 or CIN3. The speci-
ficity of cytological and virological triage was similar.
Until recently, the recommended policy in case of cervical
equivocal (borderline) or mild (low-grade) cytological abnormal-
ities consisted of the repetition of the smear and referral for col-
poscopy if the lesion persists or progresses [6, 7]. Meanwhile,
the ASCUS-LSIL triage study (AITS) has demonstrated superior
performance of triage of women with ASCUS by testing for high-
risk HPV types compared to repetition of the Pap smear or
immediate colposcopy referral. The results from the ASCUS and
LSIL triage study (ALTS), corroborated by meta-analytical work,
provide the evidence for current recommendations for reflex
hrHPV testing in case of atypical squamous cells of undeter-
mined significance [8–11]. Recommendations for managing
low-grade cytological abnormalities are not uniform, ranging
from immediate colposcopy [10] to repeat cytology and referral
if cytological abnormality is persistent [12]. The utility of reflex
hrHPV testing in case of LSIL or mild dyskaryosis is more con-
troversial: it is not recommended in the most recent guidelines
of the American Society for Colposocopy and Cervical Pathology
[10], whereas others consider introducing it in screening pro-
grammes [13]. In Australia, reflex HPV testing to triage minor
cytological abnormalities was not yet accepted, but this recom-
mendation has been criticized [14]. In this new systematic
review, we compare the HPV test positivity rate in women with
equivocal and low-grade cytological abnormalities and examine
how triage can be optimized by targeting different age groups.
Methods
Methods for retrieving published reports regarding the accuracy of HPV
triage of women with minor cervical abnormalities were described previ-
ously [4, 15]. Studies were included if the following three criteria were 
fulfilled: (1) women had an index smear showing ASCUS or low-grade
intra-epithelial lesions (LSIL) and study outcomes were reported sepa-
rately for both triage groups, (2) the high-risk probe of the Hybrid Capture
II was applied using the standard cut-off as positivity criterion (signal,
expressed as relative light units [RLU] more intense than that of a control
sample which contains 1 pg of HPV DNA per millilitre) and (3) all women
were submitted to verification with colposcopy and colposcopy-directed
biopsies and/or endocervical curettage when presence of squamous or
glandualar intra-epithelial neoplasia was suspected. From the ALTS [16,
17], we used results from two of the three trial arms: women randomly
assigned to immediate colposcopy and women randomly assigned to the
HPV DNA testing arm, where colposcopic verification was restricted to
women being HPV positive or having HSIL cytology.
In the current meta-analysis, we focus on the proportion of women
with a positive HC2 test in atypical and low-grade squamous lesions. For
this reason, inclusion criteria were relaxed and studies on management of
minor squamous cervical lesions, distinguishing atypia and low-grade
abnormalities with partial gold standard verification and/or age-stratifica-
tion of the HPV status were also included.
The 1991 and 2001 versions of The Bethesda System (TBS) and the
Terminology of the British Society of Clinical Cytology (BSCC) were used
for classification of cytology [18–20]. In the 1991 version of TBS, ASCUS
encompassed three subcategories of atypical squamous cells: (a) favour
reactive (ASC-R); (b) undetermined significance and (c) neoplasia cannot
be excluded. In TBS-2001, the first subcategory (ASC-R) was lumped with
‘negative for neoplasia or malignancy’, whereas the second and third sub-
categories were identified as ASC-US (with hyphen; atypical squamous
cells of undetermined significance) and ASC-H (atypical squamous cells,
high-grade lesion cannot be excluded), respectively. For the current meta-
analysis, we computed the number of ASCUS cases if possible from the
respective subcategories. In publications, using TBS-2001, where this was
not possible, only data on ASC-US cases were extracted. Studies reporting
data exclusively on ASC-H or atypical glandular cells were excluded. The
definition of low-grade squamous intraepithelial lesions (LSIL) remained
unchanged in TBS-1991 and TBS-2001. The BSCC terms borderline cyto -
logy and mild dyskaryosis were considered as similar to ASCUS/AS-CUS
and LSIL, respectively, but were treated separately [21].
We used a random effect model for pooling proportions [22]. Inter-
study heterogeneity was assessed with Cochrane’s Q-test [23]. The percent-
age of total variation across studies due to heterogeneity was evaluated by
the I2 measure [24]. Forest plots were drawn showing the variation of the
HC2 test positivity rate among all studies together with the pooled measure
[25, 26]. Subgroup meta-analyses were used to distinguish the respective
cytological classification systems [27]. A random-effect was also used to
pool the difference in test positivity rate between ASCUS/borderline and
LSIL/mild dyskaryosis cases [28].
The change in HPV positivity rate by age category was assessed by a
chi-square trend, which generalizes the Wilcoxon test to several ordered
groups [29]. The influence of study characteristics on inter-study hetero-
geneity was explored using a multi-variate hierarchical meta-regression
with the logit-transformed HPV positivity rate as the dependent variable
[30–32]. Relative risks were computed from the coefficients of the meta-
regression using established formulas [33, 34].
We used Stata, version 10.0 (Stata Corp., College Station, TX, USA), for
statistical analysis [27, 35].
Results
We identified 32 studies enrolling all together 26,311 women with
a cytological report of ASCUS, ASC-US or borderline dyskaryosis
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that could be included in the meta-analysis [13, 16, 36–65]. In 20
studies, high-risk HPV positivity could be derived for ASCUS
defined according to TBS-1991, in six studies for AS-CUS, defined
according to TBS-2001 and in six studies for borderline
dyskaryosis, based on the BSCC terminology. The test-positivity
rate varied between 22.8% [53] and 74.2% [55] (see Fig. 1). In
spite of the wide and statistically significant inter-study hetero-
geneity, the pooled HPV positivity rates did not differ significantly
by used cytological classification system (43.1% in ASCUS;
41.6% in ASC-US and 42.8% in borderline dyskaryosis; P for
inter-group heterogeneity  0.75). The overall pooled test positiv-
ity was 42.8% (95% CI: 39.5–46.1%).
Sixteen LSIL/mild dyskaryosis triage studies could be included
in the meta-analysis enrolling 5,389 women [13, 17, 37, 38,
41–44, 46, 50, 51, 59, 60, 64–66]. In 12 and 4 studies, respec-
tively, TBS and the BSCC were used. The lowest HC2-positivity
rate was reported by Ronco (54.6%) [64] and the highest by Rowe
(88.6%) [50] (see Fig. 2). The range of variation (highest–lowest
proportion) in the low-grade group was smaller (34.0%) than in
the ASCUS/borderline group (51.4%) but the inter-study hetero-
geneity was statistically significant in both meta-analyses (P for
Cochrane’s Q-test 0.001). The pooled hrHPV positivity rate did
not significantly vary by cytological classification system used:
75.3% in LSIL and 78.5% in mild dyskaryosis; P  0.32). The
overall pooled HC2 positivity rate was 75.9% (95% CI:
71.2–80.6%).
The difference in the HC2-positivity rate between
ASCUS/borderline dyskaryosis and LSIL/mild dyskaryosis always
was positive and significantly different from zero in all studies
except in one, where it approached significance (Fig. 3) [46]. The
overall difference in positivity rate, pooled from 15 studies, was
32.2% (95% CI: 26.8–37.7%).
In 11 studies, age-specific results were provided (Table 1) [13,
17, 39, 49, 50, 54, 56, 61, 62, 64, 67]. However, no subgroup
meta-analysis could be performed since the definition of the age
strata was not uniform. A consistent and statistically significant
negative trend with increasing age was observed in both triage
groups (P value for trend test always 0.01). In general, hrHPV
rates were higher than 80% among women younger than 30
years, with LSIL/mild dyskaryosis, at the exception of Italy, where
72% of women younger than 35 years were HPV positive. In a
triage pilot project, conducted in the UK, a rate of 51% (95% CI:
41.9–60.6%) was observed only in women of 50 years and older
with mild dyskaryosis [13].
Fig. 1 Meta-analysis of the proportion of women with ASCUS or a 
borderline Pap smear that have a positive Hybrid Capture II test.
Fig. 2 Meta-analysis of the proportion of women with LSIL or a mildly
dyskaryotic Pap smear that have a positive Hybrid Capture II test.
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Table 1 Change by age group in the HPV test positivity rate (HC2 Assay, high-risk probe, signal1 pg/mL) in the ASCUS/borderline dyskaryosis
group and LSIL/mild dyskaryosis group
ASCUS/ borderline dyskaryosis LSIL/mild dyskaryosis
Study Age group (years) N T T rate N T T rate
Shlay, 2000 30 76 37 48.7% - - -
30 119 24 20.2% - - -
P (chi-square trend)  0.001
Sherman, 2002 18–22 701 498 71.0% 383 332 86.7%
23–28 653 426 65.2% 299 263 88.0%
29 844 263 31.2% 166 124 74.7%
P (chi-square trend)  0.001 P (chi-squre trend)  0.007
Bruner, 2004 40–49 54 13 24.1% - - -
50–59 27 6 22.2% - - -
60–69 11 6 54.5% - - -
70 1 0 0.0% - - -
P (chi-square trend)  0.405
Rowe, 2004 25 446 244 54.7% - - -
26–40 372 134 36.0% - - -
41–50 224 30 13.4% - - -
50 243 30 12.3% - - -
P (chi-square trend)  0.001
Boardman, 2005 20 94 72 76.6% - - -
20–25 231 167 72.3% - - -
25 202 118 58.4% - - -
P (chi-square trend)  0.115
Kendall, 2005 ≤20 1064 622 58.5% - - -
21–25 1800 909 50.5% - - -
26–30 1049 385 36.7% - - -
31–35 828 207 25.0% - - -
36–40 847 138 16.3% - - -
41–45 646 84 13.0% - - -
46–50 462 62 13.4% - - -
51–55 252 40 15.9% - - -
56–60 169 20 11.8% - - -
60 217 34 15.7% - - -
P (chi-square trend)  0.001
Bergeron, 2006 ≤20 208 104 50.0% - - -
21–25 473 262 55.4% - - -
26–30 465 238 51.2% - - -
31–35 506 229 45.3% - - -
36–40 403 150 37.2% - - -
41–45 415 128 30.8% - - -
46–50 298 62 20.8% - - -
51–55 174 50 28.7% - - -
56–60 60 13 21.7% - - -
60 45 18 40.0% - - -
Two studies defined HPV positivity at the cut-off of 0.2 pg of
HPV DNA per millilitre and were therefore not included in the 
general meta-analysis shown in the Figs 1 and 2 [68, 69].
Nevertheless, the data of these studies and those from other
included studies that provided values for higher thresholds [17,
46, 64] were included in the meta-regression. The HPV test posi-
tivity rate was 1.60 times higher (95% CI: 1.50–1.68%) in the
LSIL/mild dyskaryosis group compared to the ASCUS/borderline
group (see Table 2). The positivity rate decreased when the cutoff
increased (–3.9%; 95% CI: –2.0 to –5.8% per additional RLU unit)
(P  0.001). The HPV positivity did not vary significantly by con-
tinent in ASCUS/borderline smears (P  0.20); however, in
LSIL/mild dyskaryisis, rates were significantly lower in European
studies compared to American studies (RR  0.83; 95% CI:
0.71–0.94%). There was no significant trend by year of publica-
tion (P 0.33). The method of collection of cellular material used
for HPV testing (Standard Transport Medium, ThinPrep [Cytyc
Corporation, Boxborough, MA, USA], BD-SurePath [TriPath
Imaging Inc., Burlington, NC, USA)], other and undefined meth-
ods) was not significant either. The test positivity was not signifi-
cantly different in studies with complete and incomplete verifica-
tion, added to the meta-analysis because of availability of age
details (P  0.36).
Discussion
Substantially higher HPV rates were observed in women with LSIL
than among women with ASCUS. This high rate compromises the
clinical utility of HPV triaging of LSIL. In the ALTS trial, further
enrolment of women with LSIL was interrupted early, when pre-
liminary analyses revealed a HC2-positivity rate of 83% [70, 71].
Testing for high-risk HPV at 12 months after the first observation
of LSIL and a negative colposcopy yielded a sensitivity to predict
subsequent CIN2 or CIN3 of 92% while referring 55% for repeat
colposcopy [72].
The American Society for Colposcopy and Cervical Pathology
(ASCCP) recommends that women with low-grade intraepithelial
lesions in cytology should be referred to colposcopy [10]. It rec-
ommends that large loop excision of the transformation zone is
acceptable only when CIN2 or CIN3 is found in histopathology.
When colposcopy and biopsies are normal or reveal only CIN1,
HPV testing after 12 months is recommended [3, 73]. The ASCCP
did not recommend reflex HPV testing in case of LSIL because of
the excessive hrHPV test-positivity rates observed in the ALTS
study. The pooled results of our meta-analysis are consistent with
the ALTS findings.
Fig. 3 Difference in Hybrid Capture 2 test-positivity rate between LSIL/mild dyskaryosis and ASCUS/borderline dyskaryosis cases.
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A British pilot study also showed that the great majority of
women with mild dyskaryosis were infected with high-risk papillo-
mavirusses, precluding efficient triage by general hrHPV DNA test-
ing. Eighty-four percent of women with mild dyskaryosis had a
positive HC2 result. In women younger than 35 years, the test
positivity rate even reached 89% [13]. To reduce the excessive
number of colposcopies, the triage policy was revised in two of
the three participating laboratories and women younger than 
35 years were referred only when, 6 months later, they remained
HPV positive or showed mild dyskaryosis or worse. The option to
postpone HPV triage in women with mild dyskaryosis aged 35 or
older was not explored nor simulated in the cost-effect analysis, in
spite of the fact that seven to eight out of ten were hrHPV positive
[74]. However, in The Netherlands, Bais and Berkhof showed that
delayed HPV and repeat cytology testing in patients with border-
line or mild dyskaryosis after 6 and 18 months is both safe and
more cost-effective than immediate HPV triage [75, 76].
Postponing triage, allows viral clearance, which over a period of 6
to 12 months can vary from 18% to 45% [75] and therefore
reduces the need for colposcopy.
From a recent Italian trial, it was suggested that hrHPV
triage could be useful in women with LSIL above 35 years of
age [64]. However, in this study, rates in hrHPV rates were 
out-lying (lowest of all studies and 22% lower than the 
pooled average).
In the case of borderline lesions, where HPV test positivity
ranges, on average, between 40% and 50%, the number of
colposcopies can be reduced considerably by virological
triage. Nevertheless, in women younger than 30–35 years, 
the specificity and the positive predictive value are low as 
well [9, 62, 67, 77].
Management of women with minor cytological cervical lesions
could be made more specific by increasing the cut-off of a posi-
tive HC2 test, but to date insufficient data are available to allow
definite conclusions on whether raising of cut-off can be done
without compromising sensitivity.
Recent data indicate that typing for the most oncogenic HPV
types, in particular for HPV16, has the potential to select
women with minor cytological lesions that have a high risk for
having or developing CIN3 [78–80]. The ROC curve, in Fig. 4,
P (chi-square trend)  0.001
Moss, 2006 20–34 1924 1239 64.4% 1335 1188 89.0%
35–49 1217 353 29.0% 373 259 69.4%
50–64 543 88 16.2% 117 60 51.3%
P (chi-square trend)  0.001 P (chi-square trend)  0.001
Selvaggi, 2006 20 57 32 56.1% - - -
21–25 189 94 49.7% - - -
26–30 159 61 38.4% - - -
31–35 91 34 37.4% - - -
36–40 30 9 30.0% - - -
41–45 32 8 25.0% - - -
46–50 41 11 26.8% - - -
51–55 30 8 26.7% - - -
56–60 22 5 22.7% - - -
60 21 4 19.0% - - -
P (chi-square trend)  0.001
Wright, 2006 ≤25 446 244 54.7% - - -
26–40 372 134 36.0% - - -
41–50 224 30 13.4% - - -
50 243 30 12.3% - - -
P (chi-square trend)  0.001
Ronco, 2007 35 241 110 45.6% 219 157 71.7%
35 516 128 24.8% 266 108 40.6%
P (chi-square trend)  0.001 P (chi-square trend)  0.002
Table 1 Continued
illustrates the change in the trade-off in sensitivity and speci-
ficity (using CIN3 as outcome) by targeting increasingly more
HPV types using ASCUS triage data from the ALTS study [78].
At each step, the type was chosen that yielded the largest gain
in sensitivity and the lowest loss in specificity when the gain in
sensitivity was equal for more types. HPV16 was the first type
to be included, showing a sensitivity of 56% for a specificity of
89%. Adding HPV31 improved the sensitivity by 8% and
decreased the specificity by 5%. The number of triage positive
women increased considerably by testing for more than 10
types, with only a very small additional detection of CIN3 cases.
Figure 4 also contains the point corresponding with the accu-
racy of HC2 [8]. HC2 targets 13 high-risk types, but also cross-
reacts with certain other high- and low-risk types [81].
Therefore, HC2 could reach sensitivity for CIN3 of 92% for a
specificity of only 51% [8]. In the Guanacaste cohort, Castle
found a 39% absolute risk for prevalent or incident CIN3 in LSIL
women infected with HPV16, whereas women infected with one
of the other 12 types included in the high-risk probe of the HC2
assay expressed a risk for CIN3 of only 10% [82]. These data
suggest that focused management of ASCUS cases carrying
HPV16 or some other types (located in the left part of the ROC
curve in Fig. 4) and more conservative follow-up of ASCUS
cases infected with other types (near the right part of the curve)
could increase triaging efficiency.
Triage with a poorly specific test unnecessarily labels women
as being at risk for cervical cancer, may induce anxiety and over-
treatment and possible subsequent adverse obstetrical effects [83,
84]. Certain molecular markers of early carcinogenic transforma-
tion could make triage more specific. One small LSIL triage study,
using tests for messenger-RNA for viral oncoproteins E6 or E7
with a follow-up of 2 years, showed a low-test positivity rate
(27%) and a high specificity (93%) for subsequent high grade CIN
[85]. Triage with GP5/CP6 PCR showed a positivity rate of
74%, a specificity of 29%, whereas the sensitivity (80%) was
equal to that of mRNA testing. Over-expression of certain 
cell cycle regulator proteins, integration of HPV DNA sequences 
in the human genome or determination of certain genetic or
immunologic profiles are potential candidates for adjunct triage
testing [86–91]. A recent meta-analysis established a clear corre-
lation between p16 over-expression and the severity of cytological
lesions, however the variation of p16 positivity was extremely
large (ranging between 10% and 100% in ASCUS and between
24% and 86% in LSIL), underlining lack of standardization in
immuno-staining, interpretation and reporting [92]. Nevertheless,
in experienced hands and using clearly defined criteria, p16
immuno-staining has shown excellent results with sensitivities for
CIN2 similar to HC2, remarkably lower positivity rates (27% in
ASCUS, 24% in LSIL) and consequently substantially higher
specificities (84% and 81%, in ASCUS and LSIL, respectively)
[93]. These promising results invite for more powerful well-
designed studies to evaluate the role of p16 and other biomarkers
that identify progressive cervical lesions and/or transforming HPV
infections. Currently, we must acknowledge the lack of good triage
studies comparing p16 with currently used alternative strategies
to triage minor cytological lesions. We note only one recent Italian
study, where p16-immunostaining was used in the background of
HPV screening to triage HPV-positive women. P16-enhanced
cytology showed a higher sensitivity and similar positive predic-
tive value for high-grade CIN compared to non-stained conven-
tional cytology [94]. In order to explore the potential to use p16
over-expression as a progression marker in triage, we propose to
All minor lesions RR lcib ucib
Cytological category
Atypical cervical cytology (  reference) 1
Low-grade cervical cytology 1.60 1.50 1.68
Year of publication (ref  1998) 0.99 0.96 1.01
RLU 0.96 0.94 0.98
Atypical cervical cytology
Cytological subcategory
ASCUS (  reference) 1
ASC-US 0.95 0.67 1.25
Borderline dyskaryosis 1.03 0.74 1.35
Continent
America (  reference) 1
Asia 1.26 0.87 1.64
Europe 0.97 0.72 1.24
Low-grade cervical cytology
Cytological subcategory
LSIL (  reference) 1.00
Mild dyskaryosis 1.10 1.01 1.15
Continent
America (  reference) 1
Asia 0.96 0.82 1.06
Europe 0.83 0.71 0.94
Table 2 Relative risk of hrHPV positivity computed from a metare-
gression
ASCUS: atypical squamous cell of undetermined significance (defined
according to 1992 version of The Bethesda System); ASC-US: atypical
squamous cell of undetermined significance (defined according to
2002 version of The Bethesda System); LSIL: low-grade squamous
intraepithelial lesion; RLU: relative light units (relative unit to express
viral load); RR: relative risk; lcib: lower 95% confidence interval bound;
ucib: upper 95% confidence interval bound.
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set up an international workshop to standardize issues of sample
processing and to define clear criteria for categorizing levels of
positivity.
Our meta-analysis also provides substance for the use of
hrHPV testing with a standardized assay as quality control
method in cytopathology which could become an alternative for
established re-screening practices [95–97]. High-risk HPV postivity
rates could be used to identify laboratories or cytotechnologists
that overcall or undercall equivocal or low-grade abnormalities.
If we should use the range –/ two standard deviations around
the pooled test-positivity rates derived from our meta-analysis,
we could consider 25–61% as benchmark for equivocal squa-
mous cytology and 57–95% for low-grade lesions. In that case,
one study could be hypothesized as overcalling ASC-US [53],
two studies as under-calling ASCUS [52, 55] and one study 
as over-calling LSIL [64]. Certainly, more research and debate 
is necessary before this idea can be translated into evidence-
based guidelines.
Conclusion
Around three quarters of women with LSIL are hrHPV positive
compared to less than half with equivocal cytological abnormal-
ities. The pooled results of our meta-analysis are in agreement
with ALTS findings and indicate that reflex hrHPV testing is
insufficiently discriminative in case of LSIL. In older women
with LSIL, hrHPV testing could be useful, but currently no obvi-
ous age threshold can be defined by lack of reported age-
specific data.
More meta-analytical work is needed, based on 5-year age
groups or using individual patient data, also including other
HPV testing assays, to provide guidance on LSIL triage. For this
purpose, we are currently obtaining age-stratified data from
published triage studies. This effort generating clinically rele-
vant evidence will require collaboration between systematic
reviewers and the principal investigators of published or ongo-
ing studies [98].
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Fig. 4 ROC curve representing the
true positivity rate (TPR  sensitiv-
ity) for CIN3 or worse disease as a
function of the false-positivity rate
(FPR  1-specificity) for increas-
ingly sensitive combinations of HPV
genotypes. The plot is constructed
using data received from the
ASCUS-LSIL triage study, and con-
cerns the accuracy of an HPV multi-
typing assay applied on women with
ASCUS [82]. The square in the upper
right corner corresponds with the
sensitivity and specificity for CIN3
of the Hybrid Capture II assay [8].
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